Open AccessClinical impact of c-MET expression and mutational status in patients with colorectal cancer lung metastases
Author(s) -
Thomas Schweiger,
Veronika Starkl,
Olaf Glueck,
Christoph Glogner,
Denise Traxler,
Julia Jedamzik,
Sandra LiebmannReindl,
Peter Birner,
Berthold Streubel,
Walter Klepetko,
Konrad Höetzenecker
Publication year - 2015
Publication title -
european journal of cardio-thoracic surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.303
H-Index - 133
eISSN - 1873-734X
pISSN - 1010-7940
DOI - 10.1093/ejcts/ezv323
Subject(s) - metastasectomy , medicine , lung , colorectal cancer , oncology , cancer research , lung cancer , hepatocyte growth factor , fusion gene , metastasis , c met , cancer , gene , receptor , biology , biochemistry
The c-MET tyrosine kinase is known to play a key role in tumour promotion in a variety of cancers. The prognostic significance of c-MET pathway alterations has previously been described in primary colorectal cancer (CRC). However, data on the expression and genetic mutational status of c-MET in CRC pulmonary metastases (PM) are lacking. We aimed to assess the clinical implications of alterations in the c-MET pathway in patients undergoing pulmonary metastasectomy.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom